GENE ONLINE|News &
Opinion
Blog

Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics

by Joy Lin
Share To

Sciwind Biosciences, a China-based company focused on metabolic diseases, has announced a collaboration with RNAi-focused SynerK to discover and develop small interfering RNA (siRNA) drugs for the treatment of liver and metabolic diseases. 

The partnership combines Sciwind’s expertise in disease biology and clinical development capabilities with SynerK’s siRNA delivery technology and experience in developing RNAi therapeutics.

Related Article: China’s Biocytogen And FineImmune Bring TCR-Mimic Antibodies And Cell Therapy Together

The siRNA Approach to Diseases 

Also known as gene silencing, RNAi sabotages mRNA to prevent their translation, thereby reducing target protein expression. siRNAs, a form of RNAi, are incorporated into a complex which binds target mRNAs to promote their degradation. 

The companies will attempt to identify new therapeutic targets for a broad range of liver and metabolic diseases and develop siRNA therapeutics against these targets. 

For delivery of the siRNA payload into cells, SynerK has developed a delivery platform that promises high delivery efficiency and a good safety profile in vitro and in vivo. Using the platform, SynerK has advanced several siRNA-based drugs into preclinical development. 

siRNAs present a lucrative and underdeveloped market opportunity in China. Besides Sciwind and SynerK, Hansoh Pharmaceuticals has reached out to two companies, Silence Therapeutics and OliX Pharmaceuticals, to develop siRNA. The deal with Silence is heavily back-loaded with $1.3 billion in milestone payments, while the OliX collaboration could potentially net the siRNA developer $450 million in milestones.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Sanofi’s siRNA Therapy Reduces Bleeds in Hemophilia, Meets Primary Endpoint
2022-07-12
Novartis Teams Up with Alnylam to Explore Targeted Liver Therapies
2022-01-07
Is the Race On for RNAi? A Chinese Pharma’s $450M Deal May Just Be the Start
2021-10-13
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!